Medicenna Therapeutics Corp. (MDNA.TO)

CAD 1.06

(-3.64%)

Total Liabilities Summary of Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.'s latest annual total liabilities in 2023 was 13.94 Million CAD , up 100.33% from previous year.
Medicenna Therapeutics Corp.'s latest quarterly total liabilities in 2024 Q1 was 15.14 Million CAD , up 8.61% from previous quarter.
Medicenna Therapeutics Corp. reported annual total liabilities of 6.96 Million CAD in 2022, up 165.55% from previous year.
Medicenna Therapeutics Corp. reported annual total liabilities of 2.62 Million CAD in 2021, down -36.18% from previous year.
Medicenna Therapeutics Corp. reported quarterly total liabilities of 13.94 Million CAD for 2023 FY, up 100.33% from previous quarter.
Medicenna Therapeutics Corp. reported quarterly total liabilities of 13.94 Million CAD for 2023 Q4, up 200.56% from previous quarter.

Annual Total Liabilities Chart of Medicenna Therapeutics Corp. (2023 - 2013)

Historical Annual Total Liabilities of Medicenna Therapeutics Corp. (2023 - 2013)

Year	Total Liabilities	Total Liabilities Growth
2023	13.94 Million CAD	100.33%
2022	6.96 Million CAD	165.55%
2021	2.62 Million CAD	-36.18%
2020	4.1 Million CAD	122.34%
2019	1.84 Million CAD	-28.15%
2018	2.57 Million CAD	16.18%
2017	2.21 Million CAD	-71.73%
2016	7.82 Million CAD	122.97%
2015	3.51 Million CAD	1102.65%
2014	291.86 Thousand CAD	-64.83%
2013	829.89 Thousand CAD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	15.14 Million CAD	8.61%
2023 FY	13.94 Million CAD	100.33%
2023 Q4	13.94 Million CAD	200.56%
2023 Q3	4.63 Million CAD	7.73%
2023 Q2	4.3 Million CAD	-7.32%
2023 Q1	4.64 Million CAD	-33.25%
2022 Q3	4.94 Million CAD	-42.75%
2022 FY	6.96 Million CAD	165.55%
2022 Q1	2.14 Million CAD	-18.08%
2022 Q2	8.64 Million CAD	302.61%
2022 Q4	6.96 Million CAD	40.63%
2021 Q2	5.43 Million CAD	9.54%
2021 Q1	4.95 Million CAD	20.72%
2021 Q4	2.62 Million CAD	11.48%
2021 Q3	2.35 Million CAD	-56.71%
2021 FY	2.62 Million CAD	-36.18%
2020 FY	4.1 Million CAD	122.34%
2020 Q4	4.1 Million CAD	85.33%
2020 Q3	2.21 Million CAD	33.82%
2020 Q2	1.65 Million CAD	7.02%
2020 Q1	1.54 Million CAD	-16.23%
2019 FY	1.84 Million CAD	-28.15%
2019 Q3	1.99 Million CAD	-2.78%
2019 Q4	1.84 Million CAD	-7.33%
2019 Q1	1.89 Million CAD	-26.18%
2019 Q2	2.05 Million CAD	8.03%
2018 Q3	2.51 Million CAD	15.59%
2018 Q4	2.57 Million CAD	2.33%
2018 FY	2.57 Million CAD	16.18%
2018 Q1	2 Million CAD	-9.58%
2018 Q2	2.17 Million CAD	8.64%
2017 Q2	6.32 Million CAD	-16.73%
2017 Q1	7.59 Million CAD	-2.98%
2017 Q3	4.53 Million CAD	-28.3%
2017 FY	2.21 Million CAD	-71.73%
2017 Q4	2.21 Million CAD	-51.2%
2016 Q2	12.36 Thousand CAD	123540.0%
2016 Q1	10.00 CAD	-99.94%
2016 FY	7.82 Million CAD	122.97%
2016 Q4	7.82 Million CAD	681.36%
2016 Q3	1 Million CAD	8001.34%
2015 Q2	5739.00 CAD	-78.06%
2015 Q4	17.21 Thousand CAD	0.0%
2015 Q1	26.15 Thousand CAD	0.0%
2015 FY	3.51 Million CAD	1102.65%
2014 FY	291.86 Thousand CAD	-64.83%
2013 FY	829.89 Thousand CAD	0.0%

Peer Total Liabilities Comparison of Medicenna Therapeutics Corp.

Name	Total Liabilities	Total Liabilities Difference
Appili Therapeutics Inc.	12.41 Million CAD	-12.306%
Eupraxia Pharmaceuticals Inc.	25.54 Million CAD	45.421%
Helix BioPharma Corp.	1.57 Million CAD	-783.027%
Microbix Biosystems Inc.	11.02 Million CAD	-26.427%
Satellos Bioscience Inc.	3.62 Million CAD	-284.741%
Oncolytics Biotech Inc.	11.25 Million CAD	-23.861%
Sernova Corp.	9.59 Million CAD	-45.356%